Conclusions: The use of simvastatin in CKD patients acutely did not reduce serum inflammation or OS markers. Possibly higher doses and/or longer treatment course of statin are required to produce drug pleiotropic effects in nondialysis CKD patients.
PMID: 19034875 [PubMed - in process] (Source: Journal of Nephrology)